Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Negative 59.9%

Neg 59.9% Neu 0% Pos 0%

Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.